ReviewJournal of gastroenterology2011
Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies.
Review in Journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Mechanisms of drug resistance in hepatocellular carcinoma.Biological procedures online · 2025Review
- GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway.BMC cancer · 2023Article
- Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma.Bioscience reports · 2020Observational
- The Significance of Secreted Phosphoprotein 1 in Multiple Human Cancers.Frontiers in molecular biosciences · 2020Article
- Genome‑wide investigation of the clinical implications and molecular mechanism of long noncoding RNA LINC00668 and protein‑coding genes in hepatocellular carcinoma.International journal of oncology · 2019Article
- Long non-coding RNAs regulation of therapeutic resistance.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Comprehensive analysis of key genes, microRNAs and long non-coding RNAs in hepatocellular carcinoma.FEBS open bio · 2018Article
- Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells.Molecular cancer · 2017Review
- The tumor promoting roles of HSP60 and HIF2α in gastric cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Klotho: a tumor suppressor and modulator of the Wnt/β-catenin pathway in human hepatocellular carcinoma.Laboratory investigation; a journal of technical methods and pathology · 2016Review
- DBD-F induces apoptosis in gastric cancer-derived cells through suppressing HIF2α expression.Cellular oncology (Dordrecht, Netherlands) · 2015Article
- LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.Oncotarget · 2015Article
- Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model.Oncotarget · 2014Article
- Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model.BMB reports · 2014Article
- Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.Journal of hematology & oncology · 2014Article
- Expression of MSP58 in hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2013Article
- Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression.Clinical and experimental medicine · 2013Article
- Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.Nature reviews. Cancer · 2013Review
- Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein.Cancer research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its incidence is still increasing. While the primary curative treatment for HCC is surgical resection, a major obstacle for the treatment of HCC is the high frequency of tumor recurrence even after curative resection. Effective palliative treatment is hindered by the evidence that HCC is frequently resistant to conventional chemotherapy and radiotherapy. Targeted therapy which specifically inhibits molecular abnormalities has emerged as a novel approach for the innovative and effective medical treatment of malignancies. In order to fulfill this promise there is an urgent need to identify the optimal targets for the treatment of HCC. A multi-kinase angiogenesis inhibitor, sorafenib, has been revealed as the first agent to show favorable overall survival in patients with advanced HCC. A new era of HCC treatment has arrived, but there has been limited improvement in survival benefits with the status quo. This review summarizes molecular targeted therapy for HCC, with a focus on angiogenesis, growth signaling, and mitosis, as well as a promising concept, "cancer stemness" for the current and potential next strategies of HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.